🕵️ Achieve Life Sciences, Inc. ($ACHV)
SEC insider & ownership activity, last 12 months · CIK 949858 · every row links its SEC filing
Over the last 12 months insiders sold $699K with no open-market buying against it. Stewart Richard Alistair sold $553K in discretionary trades (Sep–Aug). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 2 sellers, $699K (3 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Stewart Richard Alistair | 0 | – | 2 | $553K | Aug 19, 2026 |
| Mark K. Oki | 0 | – | 1 | $146K | Sep 18, 2025 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| TPG GP A, LLC | 12.6% | 13D | Apr 17, 2025 | filing ↗ | |
| James G. Coulter | 12.6% | 13D | Apr 17, 2025 | filing ↗ | |
| Jon Winkelried | 12.6% | 13D | Apr 17, 2025 | filing ↗ | |
| Logos Global Management LP | 10.0% | 13G | Aug 17, 2026 | filing ↗ | |
| Logos Global Management GP LLC | 10.0% | 13G | Aug 17, 2026 | filing ↗ | |
| Arsani William | 10.0% | 13G | Aug 17, 2026 | filing ↗ | |
| venBio Global Strategic GP V, LLC | 10.0% | 13D | Apr 15, 2026 | filing ↗ | |
| venBio Global Strategic Fund V, L.P. | 10.0% | 13D | Apr 15, 2026 | filing ↗ | |
| Paradigm BioCapital Advisors LP | 9.2% | 13G | Apr 24, 2026 | filing ↗ | |
| Paradigm BioCapital Advisors GP LLC | 9.2% | 13G | Apr 24, 2026 | filing ↗ | |
| Senai Asefaw, M.D. | 9.2% | 13G | Apr 24, 2026 | filing ↗ | |
| Franklin Resources, Inc. | 8.3% | 13G | Jul 28, 2026 | filing ↗ | |
| Franklin Advisers, Inc. | 8.3% | 13G | Jul 28, 2026 | filing ↗ | |
| Paradigm BioCapital International Fund Ltd. | 8.1% | 13G | Apr 24, 2026 | filing ↗ | |
| Frazier Life Sciences Public Fund, L.P. | 6.5% | 13G | Apr 24, 2026 | filing ↗ | |
| Fhmlsp, L.P. | 6.5% | 13G | Apr 24, 2026 | filing ↗ | |
| Fhmlsp, L.L.C. | 6.5% | 13G | Apr 24, 2026 | filing ↗ | |
| Alyeska Investment Group, L.P. | 5.6% | 13G | Nov 14, 2025 | filing ↗ | |
| Alyeska Fund GP, LLC | 5.6% | 13G | Nov 14, 2025 | filing ↗ | |
| Anand Parekh | 5.6% | 13G | Nov 14, 2025 | filing ↗ | |
| Janus Henderson Group Ltd. | 5.4% | 13G | Aug 13, 2026 | filing ↗ | |
| Venrock Healthcare Capital Partners III, L.P. | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| VHCP Co-Investment Holdings III, LLC | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| Venrock Healthcare Capital Partners EG, L.P. | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| VHCP Management III, LLC | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| VHCP Management EG, LLC | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| Nimish Shah | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| Bong Y. Koh | 5.2% | 13G | Apr 24, 2026 | filing ↗ | |
| BlackRock, Inc. | 5.1% | 13G | Jul 27, 2026 | filing ↗ | |
| Logos Global Master Fund LP | 5.1% | 13G | Aug 17, 2026 | filing ↗ | |
| Logos GP LLC | 5.1% | 13G | Aug 17, 2026 | filing ↗ | |
| VIVO Opportunity, LLC | 5.0% | 13G | Jul 8, 2026 | filing ↗ | |
| Logos Opportunities Fund V LP | 5.0% | 13G | Aug 17, 2026 | filing ↗ | |
| Logos Opportunities V GP LLC | 5.0% | 13G | Aug 17, 2026 | filing ↗ | |
| Graham Walmsley | 5.0% | 13G | Aug 17, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Stewart Richard Alistair | $155K | Aug 19, 2026 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Other events (8.01) | Aug 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 14, 2026 | filing ↗ |
| Earnings (2.02) | Aug 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 11, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | Jul 2, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jul 2, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 2, 2026 | filing ↗ |
| Officer/director changes (5.02) | May 29, 2026 | filing ↗ |
| Earnings (2.02) | May 7, 2026 | filing ↗ |
| Officer/director changes (5.02) | May 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 7, 2026 | filing ↗ |
| Material agreement (1.01) | Apr 15, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Apr 15, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 15, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 15, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 15, 2026 | filing ↗ |
| Earnings (2.02) | Mar 24, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 24, 2026 | filing ↗ |
| Earnings (2.02) | Nov 6, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 6, 2025 | filing ↗ |
| Officer/director changes (5.02) | Oct 6, 2025 | filing ↗ |